We are live on ! Find out more
INM icon

InMed Pharmaceuticals
INM

9 hedge funds and large institutions have $234K invested in InMed Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

0.31% less ownership

Funds ownership: 0.92% → 0.62% (-0.31%)

18% less funds holding

Funds holding: 11 → 9 (-2)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

73% less capital invested

Capital invested by funds: $877K → $234K (-$642K)

Holders
9
Holders Change
-2
Holders Change %
-18.18%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
1
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$59.6K
2
AC
Armistice Capital
New York
+$24.1K
3
BlackRock
BlackRock
New York
+$202
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$67

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$101K
2
Millennium Management
Millennium Management
New York
-$91K
3
Bank of America
Bank of America
North Carolina
-$45K
4
UBS Group
UBS Group
Switzerland
-$16.7K
5
TRCT
Tower Research Capital (TRC)
New York
-$7K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$196K +$24.1K +358 +8%
VF
2
Virtu Financial
New York
$36K +$59.6K +886 New
UBS Group
3
UBS Group
Switzerland
$1.68K -$16.7K -248 -86%
TWC
4
TD Waterhouse Canada
Ontario, Canada
$252 – – –
BlackRock
5
BlackRock
New York
$101 +$202 +3 New
AWM
6
AllSquare Wealth Management
New York
$42 – – –
FDCDDQ
7
Federation des caisses Desjardins du Quebec
Quebec, Canada
$38 – – –
National Bank of Canada
8
National Bank of Canada
Quebec, Canada
$14 – – –
ASN
9
Advisory Services Network
Georgia
$12 – – –
TWA
10
TCI Wealth Advisors
Arizona
$10 – – –
Morgan Stanley
11
Morgan Stanley
New York
$2 -$471 -7 Closed
GCM
12
Gables Capital Management
Florida
$2 – – –
SM
13
Sabby Management
Florida
– -$101K -764 Closed
Millennium Management
14
Millennium Management
New York
– -$91K -696 Closed
Bank of America
15
Bank of America
North Carolina
– -$45K -339 Closed
TRCT
16
Tower Research Capital (TRC)
New York
– -$7K -53 Closed
Royal Bank of Canada
17
Royal Bank of Canada
Ontario, Canada
– +$67 +1 New

INM Hedge Fund Activity: Q4 2022 in Review

9 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q4 2022, worth a combined $234K — down 73% from $877K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of INM and 3 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was Virtu Financial, opening a new position worth an estimated $59.6K. The largest seller was Sabby Management, exiting entirely with an estimated $101K sold.

  • 9 institutional investors held InMed Pharmaceuticals (INM) as of Q4 2022, down from 11 in Q3 2022.
  • Funds reported $234K of InMed Pharmaceuticals stock for Q4 2022, down 73% quarter-over-quarter.
  • 3 funds opened new InMed Pharmaceuticals positions in Q4 2022 and 5 closed out, a net change of -2 holders.
  • The largest InMed Pharmaceuticals buyer in Q4 2022 was Virtu Financial, an estimated $59.6K added.
  • The largest InMed Pharmaceuticals seller in Q4 2022 was Sabby Management, an estimated $101K sold.

Based on aggregated 13F filings for Q4 2022.